Literature DB >> 11036003

Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans.

O Marchetti1, J M Entenza, D Sanglard, J Bille, M P Glauser, P Moreillon.   

Abstract

Recent observations demonstrated that fluconazole plus cyclosporine (Cy) synergistically killed Candida albicans in vitro. This combination was tested in rats with C. albicans experimental endocarditis. The MICs of fluconazole and Cy for the test organism were 0.25 and >10 mg/liter, respectively. Rats were treated for 5 days with either Cy, amphotericin B, fluconazole, or fluconazole-Cy. Although used at high doses, the peak concentrations of fluconazole in the serum of rats (up to 4.5 mg/liter) were compatible with high-dose fluconazole therapy in humans. On the other hand, Cy concentrations in serum (up to 4.5 mg/liter) were greater than recommended therapeutic levels. Untreated rats demonstrated massive pseudohyphal growth in both the vegetations and the kidneys. However, only the kidneys displayed concomitant polymorphonuclear infiltration. The therapeutic results reflected this dissociation. In the vegetations, only the fungicidal fluconazole-Cy combination significantly decreased fungal densities compared to all groups, including amphotericin B (P < 0.0001). In the kidneys, all regimens except the Cy regimen were effective, but fluconazole-Cy remained superior to amphotericin B and fluconazole alone in sterilizing the organs (P < 0.0001). While the mechanism responsible for the fluconazole-Cy interaction is hypothetical, this observation opens new perspectives for fungicidal combinations between azoles and other drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036003      PMCID: PMC101583          DOI: 10.1128/AAC.44.11.2932-2938.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

Review 1.  ABC transporters: from microorganisms to man.

Authors:  C F Higgins
Journal:  Annu Rev Cell Biol       Date:  1992

2.  Isogenic strain construction and gene mapping in Candida albicans.

Authors:  W A Fonzi; M Y Irwin
Journal:  Genetics       Date:  1993-07       Impact factor: 4.562

3.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

Review 4.  Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.

Authors:  A F List
Journal:  Leukemia       Date:  1996-06       Impact factor: 11.528

5.  Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species.

Authors:  U K Garcha; E Brummer; D A Stevens
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

6.  Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.

Authors:  A Louie; Q F Liu; G L Drusano; W Liu; M Mayers; E Anaissie; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Comparison of fluconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-C. albicans strains.

Authors:  M D Witt; T Imhoff; C Li; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Authors:  D Sanglard; K Kuchler; F Ischer; J L Pagani; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

10.  Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.

Authors:  E J Anaissie; D P Kontoyiannis; C Huls; S E Vartivarian; C Karl; R A Prince; J Bosso; G P Bodey
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

View more
  51 in total

Review 1.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

2.  Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.

Authors:  Javier Afeltra; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

4.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.

Authors:  William J Steinbach; Nina Singh; Jackie L Miller; Daniel K Benjamin; Wiley A Schell; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

5.  Calcineurin is required for Candida albicans to survive calcium stress in serum.

Authors:  Jill R Blankenship; Joseph Heitman
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

6.  In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

Authors:  Eric Dannaoui; Patrick Schwarz; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 7.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

8.  Mitogen-activated protein kinase stimulation of Ca(2+) signaling is required for survival of endoplasmic reticulum stress in yeast.

Authors:  Myriam Bonilla; Kyle W Cunningham
Journal:  Mol Biol Cell       Date:  2003-06-27       Impact factor: 4.138

Review 9.  Signaling cascades as drug targets in model and pathogenic fungi.

Authors:  Robert J Bastidas; Jennifer L Reedy; Helena Morales-Johansson; Joseph Heitman; Maria E Cardenas
Journal:  Curr Opin Investig Drugs       Date:  2008-08

10.  Calcineurin is essential for virulence in Candida albicans.

Authors:  Teresa Bader; Barbara Bodendorfer; Klaus Schröppel; Joachim Morschhäuser
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.